Tempest Therapeutics Announces Up to $7.5 Million Private Placement
Tempest Therapeutics (TPST) announced a private placement of 3.1M shares and warrants, raising $2.5M, with potential additional proceeds of $5M if warrants are exercised. Proceeds will be used for working capital. The offering is expected to close on September 14, 2026, subject to conditions.
How this was made
The 30-second read
Why it matters
The $2.5M private placement provides short‑term liquidity but introduces dilution risk; investors may monitor warrant exercise levels.
Market read
A small secondary offering for a micro‑cap biotech; limited immediate market relevance.
What to watch
Potential future warrant exercise could increase dilution if stock price rises.
Background
Tempest Therapeutics is a clinical-stage biotech developing in vivo CAR‑T therapies. The company needed additional working capital.
Ticker impact
Tempest Therapeutics announced a private placement of 3.1M shares and warrants to raise about $2.5M, closing around Sep 14, 2026.
Minor upside potential if dilution concerns are outweighed by cash runway extension.
The raise is small relative to market cap and may be priced in, but provides needed liquidity.
Market effects
Adds modest funding to the biotech sector; unlikely to shift sector dynamics.
US biotech market sees a small secondary offering.
Limited global impact.
Counterpoint
The raise may signal cash constraints, suggesting caution.
Key entities
- CompanyTempest Therapeutics, Inc.
Clinical‑stage biotech issuing the private placement.
- Placement AgentH.C. Wainwright & Co.
Exclusive placement agent for the offering.
